SCHEMBL12680353

SCHEMBL12680353

COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NC(=O)CCCNC(=O)CCCC(=O)O)c2)c(OC)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 4/20 0.71
HDAC4 P56524 4/20 0.71
HDAC1 Q13547 4/20 0.71
HDAC6 Q9UBN7 4/20 0.71
HDAC3 O15379 2/20 0.71
HDAC7 Q8WUI4 2/20 0.71
HDAC2 Q92769 2/20 0.71
HDAC10 Q969S8 2/20 0.71
HDAC11 Q96DB2 2/20 0.71
HDAC8 Q9BY41 2/20 0.71
HDAC9 Q9UKV0 2/20 0.71
HDAC5 Q9UQL6 2/20 0.71
MET P08581 1/20 0.64
NQO2 P16083 1/20 0.64
FECH P22830 1/20 0.64
CLK3 P49761 1/20 0.64
POLB P06746 4/20 0.44
EGFR P00533 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12132478 0.95 PLK1 (0.79) PLK1HDAC4HDAC1HDAC6HDAC3
SCHEMBL12132314 0.89 PLK1 (0.85) PLK1HDAC4HDAC1HDAC6HDAC3
SCHEMBL1122888 0.86 PLK1 (0.78) PLK1HDAC4HDAC1HDAC6HDAC3
SCHEMBL1122890 0.86 PLK1 (0.78) PLK1HDAC4HDAC1HDAC6HDAC3
SCHEMBL12680352 0.86 PLK1 (0.62) PLK1HDAC4HDAC1HDAC6HDAC3
SCHEMBL1123003 0.85 PLK1 (0.78) PLK1HDAC4HDAC1HDAC6HDAC3
SCHEMBL1123005 0.85 PLK1 (0.78) PLK1HDAC4HDAC1HDAC6HDAC3
SCHEMBL1123132 0.85 PLK1 (0.78) PLK1HDAC4HDAC1HDAC6HDAC3
SCHEMBL12680343 0.84 PLK1 (0.57) PLK1HDAC4HDAC1HDAC6HDAC3
SCHEMBL12132363 0.84 PLK1 (0.85) PLK1HDAC4HDAC1HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273787-B2 Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions ONCONOVA THERAPEUTICS, INC (US) 2012-09-25 US disclosed
US-8273787-B2 Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions ONCONOVA THERAPEUTICS, INC (US) 2012-09-25 US disclosed
US-20100022615-A1 ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS ONCONOVA THERAPEUTICS, INC (US) 2010-01-28 US disclosed
US-20100022615-A1 ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS ONCONOVA THERAPEUTICS, INC (US) 2010-01-28 US disclosed
WO-2008033475-A2 ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS ONCONOVA THERAPEUTICS, INC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022615-A1 ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS CD40, TNFRSF9, NGFR PLK1 297/4885HDAC4 3320/4885HDAC1 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.